Ludwig Institute for Cancer Research Limited

Other

Institut National De La Sante Et De La Recherche Medicale

Oxford University Innovation Limited

Sanofi Pasteur Inc.

University of California

Cornell Research Foundation Inc.

Vrije Universiteit Brussel

Universite Catholique De Louvain

Leiden University

University of Leiden

Ludwig Institute of Cancer Research

Ludwig Institute for Cancer

Ludwig Institute

Thierry R Boon-Falleur

Pierre Van Der Bruggen

Pierre G Coulie

Benoit Van Den Eynde

Aline Van Pel

Vincent Brichard

Etienne De Plaen

Francis Brasseur

Catia Traversari

Sophie Lucas

Charles De Smet

Christophe Lurquin

Pascal Chaux

Bernard Lethe

Thomas Wolfel

Vincent Stroobant

Etienne DePlaen

Jean-Christophe Renauld

Nicolas Van Baren

Beatrice Gaugler

Pierre Van Den Bruggen

Charles DeSmet

Hideyuki Ikeda

Olivier DeBacker

Daniele Godelaine

Claude Wildmann

Nathalie Demotte

Guy R Cornelis

Jean-Christope Renauld

Yi Zhang

Jean Herman

Judy Bastin

Alan Townsend

Francine Jotereau

Kris Thielemans

Yannick Guilloux

Marie-Therese Duffour

Rosalie Luiten

Thomas W&ouml;lfel

W M Kast

Béatrice Guagler

Katharina Fleischauer

Jurgen Kurthals

Susanna Mandruzzato

Cornelis J Melief

Thomas Gajewski

James Tartaglia

Patrick Chomez

Erwin Schultz

John A Tine

Philippe Moingeon

B&eacute;atrice Guagler

Javier Carrasco

Anne M Boland

Pierre Vander Bruggen

Olivier De Backer

Bernard Lethé

Valerie Martelange

Pierre B Van Der Bruggen

Christophe Lurguin

Val&eacute;rie Martelange

Wenbin Ma

Catie Traversari

M W Visseren

Catherine Germeau

Pascale Boel

Immanuel Luescher

Pascale Bo{haeck Over (e)}l

Guy Warnier

Jean-Pierre Szikora

Lloyd J Old

Yao-tseng Chen

Elisabeth Stockert

Jacques Van Snick

Wolfgang J Rettig

Pilar Garin-Chesa

Neil L Berinstein

Pedro Romero

Donata Rimoldi

Fredric A Gorin

Sandra Morel

Lan-Qing Huang

Vincenzo Russo

Yachi Chen

Pierre Van Der Bruggan

Pascale Bo&euml;l

G&eacute;rard De Giiovanni

Annie Ooms

Beno&icirc;t Van Den Eynde

Beno&iacute;t Van Den Eynde

Guy Cornelius

De Smet Charles

Valérie Martelange

Bernard Leth&eacute;

Christoph Lurquin

Marjan J Visseren

Nathalie Vigneron

M J Visseren

Leonora Heidecker

Cornelis J M Melief

The invention relates to methods and compositions which modulate T lymphocyte activity. It has been found that two, T lymphocyte receptors, especially TCR and CD8, are present at a distance from each other on T lymphocyte surfaces. Via use of modulators which change the distance between these receptors, the activity of the T lymphocyte is modulated.

Method for modulating activity of T lymphocytes

Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.

Tumour rejection antigens

The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.

Immunogenic polypeptides encoded by MAGE minigenes and uses thereof

The invention describes SAGE (sdph3.10) and sdp3.5 tumor associated nucleic acids, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acid molecules, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a sdph3.10 and/or sdp3.5 gene product.

Tumor associated amino acids and uses therefor

This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, &#x2203;microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.

MAGE-C2 antigenic peptides and uses thereof

The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.

Lage-1 tumor associated nucleic acids

This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, &#x3b2;microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.

The invention relates to new members of the GAGE family referred to as GAGE-7B and GAGE-8. There are differences between these two molecules and the previously described members of the GAGE family on the genomic DNA, complementary DNA, and amino acid level.

Isolated GAGE-7B and 8 proteins

LAGE-1 tumor associated nucleic acids

The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.

Isolated proteins MAGE-4 and MAGE-41

Tumor associated nucleic acids and uses therefor

The invention describes HLA class II binding peptides encoded by the MAGE tumor associated genes, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of MAGE genes.

MAGE peptides presented by HLA class II molecules

The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.

MAGE-A3 peptides presented by HLA class II molecules

Growing community of inventors

Brussels, Belgium

Thierry R Boon-Falleur